7,655 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Traveka Wealth LLC

Traveka Wealth LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, HoldingsChannel.com reports. The firm bought 7,655 shares of the company’s stock, valued at approximately $1,200,000.

A number of other hedge funds have also recently bought and sold shares of the company. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the third quarter worth approximately $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the third quarter worth approximately $37,000. Tower View Wealth Management LLC raised its stake in Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC raised its stake in shares of Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $152.31 on Wednesday. The company has a market capitalization of $367.03 billion, a price-to-earnings ratio of 11.03, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97. The firm’s fifty day moving average price is $157.79 and its 200 day moving average price is $156.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period last year, the business earned $2.35 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on JNJ. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, Morgan Stanley cut their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.